ImmuPharma (LON:IMM) Trading Up 9.3% – Should You Buy?

Shares of ImmuPharma plc (LON:IMMGet Free Report) traded up 9.3% during mid-day trading on Friday . The company traded as high as GBX 4.50 ($0.06) and last traded at GBX 3.94 ($0.05). 31,560,066 shares traded hands during mid-day trading, an increase of 60% from the average session volume of 19,683,289 shares. The stock had previously closed at GBX 3.60 ($0.04).

ImmuPharma Stock Up 9.3 %

The company’s fifty day simple moving average is GBX 1.75 and its 200 day simple moving average is GBX 1.73. The firm has a market capitalization of £16.39 million, a PE ratio of -393.60 and a beta of 1.53.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Articles

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.